Correction to: Tcf‑1 protects anti‑tumor TCR‑engineered CD8+ T‑cells from GzmB mediated self‑destruction

Correction to: Tcf‑1 protects anti‑tumor TCR‑engineered CD8⁺ T‑cells from GzmB mediated self‑destruction

Cancer Immunol Immunother. 2022 Dec;71(12):2899. doi: 10.1007/s00262-022-03233-1.

Brendan Zangari¹, Takemasa Tsuji^{2

3}, Junko Matsuzaki^{2

3}, Hemn Mohammadpour¹, Cheryl Eppolito¹, Sebastiano Battaglia^{1

4}, Fumito Ito⁵, Thinle Chodon^{2

3}, Richard Koya^{2

3}, A J Robert McGray¹, Kunle Odunsi^{6

7}

¹ Department of Immunology, Roswell Park Comprehensive Cancer Center, Buffalo, NY, USA.
² University of Chicago Medicine Comprehensive Cancer Center, 5841 S Maryland Ave, Chicago, IL, 60637, USA.
³ Department of Obstetrics and Gynecology, University of Chicago, Chicago, IL, USA.
⁴ Department of Genetics and Genomics and Bioinformatics, Roswell Park Comprehensive Cancer Center, Buffalo, NY, USA.
⁵ Keck School of Medicine, University of Southern California, Los Angeles, CA, USA.
⁶ University of Chicago Medicine Comprehensive Cancer Center, 5841 S Maryland Ave, Chicago, IL, 60637, USA. odunsia@bsd.uchicago.edu.
⁷ Department of Obstetrics and Gynecology, University of Chicago, Chicago, IL, USA. odunsia@bsd.uchicago.edu.

No abstract available